Therapy

Anticancer Agent Licensed To Antisoma's Targeted Apoptosis Program

Published in Cancer Weekly, October 16th, 2001

Antisoma PLC (ASM, ASOM) a U.K.-based pharmaceutical company developing novel targeted cancer therapies, has strengthened its targeted apoptosis research program through an in-licensing agreement with the U.S. National Institutes of Health (NIH).

Targeted apoptosis combines the tumor-specific targeting ability of monoclonal antibodies with enzymes that attack the cells' genetic machinery, triggering cancer cell death.

Antisoma has acquired exclusive worldwide rights to use of the enzyme, recombinant cytotoxic RNase, in combination with monoclonal antibodies that target PEM (polymorphic epithelial mucin) and CEA (carcinoembryonic antigen) - protein...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry